Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

TY - JOUR

T1 - Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure

T2 - safety and efficacy data in a series of 21 patients from Europe and the USA

AU - Douglas, K. W.

AU - Parker, A. N.

AU - Hayden, P. J.

AU - Rahemtulla, A.

AU - D'Addio, A.

AU - Lemoli, R. M.

AU - Rao, K.

AU - Maris, M.

AU - Pagliuca, Tony

AU - Uberti, J.

AU - Scheid, C.

AU - Noppeney, R.

AU - Cook, G.

AU - Bokhari, S. W.

AU - Worel, N.

AU - Mikala, G.

AU - Masszi, T.

AU - Taylor, R.

AU - Treisman, J.

PY - 2012/1

Y1 - 2012/1

N2 - We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed mobilisation by conventional means (plerixafor used up-front for 4 patients). For 15 patients, the plerixafor dose was reduced to 0.16 mg/kg/day, with a subsequent dose increase in one case to 0.24 mg/kg/day. The remaining six patients received a standard plerixafor dosage at 0.24 mg/kg/day. Scheduling of plerixafor and apheresis around dialysis was generally straightforward. Following plerixafor administration, all patients underwent apheresis. A median CD34+ cell dose of 4.6 x 10(6) per kg was achieved after 1 (n=7), 2 (n=10), 3 (n=3) or 4 (n=1) aphereses. Only one patient failed to achieve a sufficient cell dose for transplant: she subsequently underwent delayed re-mobilisation using G-CSF with plerixafor 0.24 mg/kg/day, resulting in a CD34+ cell dose of 2.12 x 10(6)/kg. Sixteen patients experienced no plerixafor toxicities; five had mild-to-moderate gastrointestinal symptoms that did not prevent apheresis. Fifteen patients have progressed to autologous transplant, of whom 12 remain alive without disease progression. Two patients recovered endogenous renal function post autograft, and a third underwent successful renal transplantation. Plerixafor is highly effective in mobilising PBSC in this difficult patient group.

AB - We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed mobilisation by conventional means (plerixafor used up-front for 4 patients). For 15 patients, the plerixafor dose was reduced to 0.16 mg/kg/day, with a subsequent dose increase in one case to 0.24 mg/kg/day. The remaining six patients received a standard plerixafor dosage at 0.24 mg/kg/day. Scheduling of plerixafor and apheresis around dialysis was generally straightforward. Following plerixafor administration, all patients underwent apheresis. A median CD34+ cell dose of 4.6 x 10(6) per kg was achieved after 1 (n=7), 2 (n=10), 3 (n=3) or 4 (n=1) aphereses. Only one patient failed to achieve a sufficient cell dose for transplant: she subsequently underwent delayed re-mobilisation using G-CSF with plerixafor 0.24 mg/kg/day, resulting in a CD34+ cell dose of 2.12 x 10(6)/kg. Sixteen patients experienced no plerixafor toxicities; five had mild-to-moderate gastrointestinal symptoms that did not prevent apheresis. Fifteen patients have progressed to autologous transplant, of whom 12 remain alive without disease progression. Two patients recovered endogenous renal function post autograft, and a third underwent successful renal transplantation. Plerixafor is highly effective in mobilising PBSC in this difficult patient group.

KW - plerixafor

KW - myeloma

KW - kidney failure

KW - dialysis

KW - autologous HSC transplant

KW - BLOOD STEM-CELLS

KW - MULTIPLE-MYELOMA

KW - AUTOLOGOUS TRANSPLANTATION

KW - G-CSF

KW - CHEMOTHERAPY

KW - LENALIDOMIDE

KW - COLLECTION

KW - MOBILIZERS

KW - LYMPHOMA

KW - THERAPY

U2 - 10.1038/bmt.2011.9

DO - 10.1038/bmt.2011.9

M3 - Article

SN - 0268-3369

VL - 47

SP - 18

EP - 23

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 1

ER -